AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22737998 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 61
Study 21098908 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MR) with cross-sectional area (CSA) measures
Number of subjects: 17
Study 19836952 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (specific dosage and duration not mentioned)
Number of subjects: 979
Study 16872374 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium animalis ssp. lactis (BB‐12) and Lactobacillus paracasei ssp. paracasei (CRL‐431) supplementation (0, 10^8, 10^9, 10^10, 10^11 CFU day(‐1) for 3 weeks)
Number of subjects: 71
Study 16872374 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis ssp. lactis (BB‐12) and Lactobacillus paracasei ssp. paracasei (CRL‐431) supplementation
Number of subjects: 71
Study 12926979 — intervention group
Group type: EXPERIMENTAL
Intervention: BOTOX®
Number of subjects: 264
Study 12926979 — intervention group
Group type: COMPARATOR
Intervention: Topical agents (aluminum chloride) and iontophoresis
Number of subjects: 264
Study 10706303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic technique
Number of subjects: 12
Study 10706303 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular laparoscopic technique
Number of subjects: 12
Study 10706303 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 12
Study 9133133 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gut lavage
Number of subjects: 100
Study 9133133 — intervention group
Group type: COMPARATOR
Intervention: Oral polyethylene glycol solution (Fordtran)
Number of subjects: 100
Study 9133133 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepacol
Number of subjects: 100
Study 8363995 — intervention group
Group type: EXPERIMENTAL
Intervention: tropisetron (5 mg/day; n = 115)
Number of subjects: 231
Study 8363995 — intervention group
Group type: COMPARATOR
Intervention: optimal standard therapy (n = 116)
Number of subjects: 231
Study 2424249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% minoxidil in unguentum merck
Number of subjects: 50
Study 2424249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (unguentum merck alone)
Number of subjects: 50
Study 29198901 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 444
Study 29198901 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 444
Study 29198901 — intervention group
Group type: COMPARATOR
Intervention: CT vs MRI
Number of subjects: 444
Study 27721123 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided ACT
Number of subjects: 152
Study 25026866 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR)
Number of subjects: 8
Study 25026866 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP)
Number of subjects: 8
Study 25026866 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) for ground-glass nodules
Number of subjects: 8
Study 25026866 — intervention group
Group type: COMPARATOR
Intervention: Filtered Back Projection (FBP) for ground-glass nodules
Number of subjects: 8
Study 23290427 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based surveys via e-mail
Number of subjects: 92
Study 23290427 — intervention group
Group type: COMPARATOR
Intervention: In-person or telephone follow-up surveys
Number of subjects: 92
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin monotherapy
Number of subjects: 0
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin as initial combination therapy with metformin or pioglitazone
Number of subjects: 0
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin add-on therapy
Number of subjects: 0
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin as add-on treatment to metformin
Number of subjects: 0
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin as add-on treatment to pioglitazone
Number of subjects: 0
Study 20205490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 19119599 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of p53 protein in NPSC
Number of subjects: 67
Study 19119599 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of p63 protein in NPSC
Number of subjects: 67
Study 19119599 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between p53 and p63 protein in NPSC
Number of subjects: 67
Study 19119599 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of p73 protein in NPSC
Number of subjects: 67
Study 16606452 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg repaglinide
Number of subjects: 12
Study 16606452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no repaglinide)
Number of subjects: 12
Study 15130047 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group
Number of subjects: 26
Study 15130047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 11878736 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine and hyaluronidase 150 U ml(‐1) in a volume of 4 or 5 ml
Number of subjects: 40
Study 9779169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotics (Unasyn and Aztreonam)
Number of subjects: 228
Study 9779169 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotics only (Unasyn)
Number of subjects: 228
Study 8154635 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12525 200 mg
Number of subjects: 62
Study 8154635 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12525 25 mg
Number of subjects: 62
Study 8154635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3163364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (31% of total kcal)/low cholesterol (193 mg/d) (LFLC)
Number of subjects: 4
Study 3163364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/usual cholesterol (504 mg/d) (LFUC)
Number of subjects: 4
Study 3163364 — intervention group
Group type: COMPARATOR
Intervention: Usual fat (46% of total kcal)/low cholesterol (UFLC)
Number of subjects: 4
Study 3163364 — intervention group
Group type: COMPARATOR
Intervention: Usual fat/usual cholesterol (UFUC)
Number of subjects: 4
Study 3163364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat intake
Number of subjects: 4
Study 3163364 — intervention group
Group type: COMPARATOR
Intervention: Usual fat intake
Number of subjects: 4
Study 31905383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 743
Study 31905383 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Alafenamide (TAF)-based regimen
Number of subjects: 743
Study 30246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg thrice daily)
Number of subjects: 3800
Study 30246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2000 mg once daily)
Number of subjects: 3800
Study 30246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg four times daily)
Number of subjects: 3800
Study 30246150 — intervention group
Group type: EXPERIMENTAL
Intervention: Any combination of metoclopramide, ceftriaxone, paracetamol
Number of subjects: 3800
Study 30246150 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3800
Study 27176931 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + Postoperative Radiotherapy (PORT) (median dose: 45 Grays)
Number of subjects: 599
Study 27176931 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 599
Study 25615888 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop technology (real-time continuous glucose monitoring with overnight closed-loop)
Number of subjects: 24
Study 23758464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse Plus
Number of subjects: 70
Study 23758464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronamel
Number of subjects: 70
Study 20627269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 107
Study 20627269 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 107
Study 20627269 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 107
Study 18771643 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL7013 Gel
Number of subjects: 36
Study 16520686 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg/day, median stable dose 300 mg/day)
Number of subjects: 245
Study 16520686 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (previous randomized modafinil group)
Number of subjects: 245
Study 16520686 — intervention group
Group type: COMPARATOR
Intervention: Placebo (previous placebo group)
Number of subjects: 245
Study 16520686 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (for former modafinil responders and placebo nonresponders)
Number of subjects: 245
Study 16520686 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (general outcome)
Number of subjects: 245
Study 12934740 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux for 1 week
Number of subjects: 0
Study 12934740 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux for 4 weeks
Number of subjects: 0
Study 12934740 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin for 1 week
Number of subjects: 0
Study 12934740 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 0
Study 11145438 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b during induction, maintenance and relapse (NMSG 4/90)
Number of subjects: 0
Study 11145438 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon as maintenance after high-dose chemotherapy with stem cell support (NMSG 5/94)
Number of subjects: 0
Study 9181655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 160 mg i.v. once daily for 2 days + Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Number of subjects: 73
Study 9181655 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Number of subjects: 73
Study 8476407 — intervention group
Group type: EXPERIMENTAL
Intervention: Worrisome thinking (General-Worry)
Number of subjects: 0
Study 8476407 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0
Study 8476407 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoughts during worry
Number of subjects: 0
Study 8476407 — intervention group
Group type: EXPERIMENTAL
Intervention: Images during worry
Number of subjects: 0
Study 8476407 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect experienced during worry
Number of subjects: 0
Study 3535021 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS coated tablets
Number of subjects: 189
Study 3535021 — intervention group
Group type: COMPARATOR
Intervention: CBS chewing tablets
Number of subjects: 189
Study 3535021 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS coated tablets and CBS chewing tablets
Number of subjects: 189
Study 30285814 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 135
Study 30285814 — intervention group
Group type: COMPARATOR
Intervention: Standard disease information only (Control)
Number of subjects: 135
Study 27733181 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative psychological therapy for depression (REFRAMED)
Number of subjects: 20
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary fiber intake (quartile 4 vs. quartile 1)
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble fiber intake
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume fiber intake
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber intake
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fiber intake
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable fiber intake
Number of subjects: 3313
Study 24553693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit fiber intake
Number of subjects: 3313
Study 22889722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (SSRIs)
Number of subjects: 2346
Study 22889722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (TCAs)
Number of subjects: 2346
Study 22889722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (Miscellaneous)
Number of subjects: 2346
Study 22889722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2346
Study 20584776 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) during exercise
Number of subjects: 30
Study 20584776 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced CFI reserve
Number of subjects: 30
Study 20584776 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary collateral conductance during exercise
Number of subjects: 30
Study 18672988 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide mouthrinse
Number of subjects: 77
Study 18672988 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (0.20%) mouthrinse
Number of subjects: 77
Study 15815935 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume/low intensity exercise training for 6 months
Number of subjects: 6
Study 14508313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20
Study 14508313 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 10097932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) at an initial dosage of 9.3 mg.kg‐1.day‐1 tapered to 7.0 mg.kg‐1.day‐1 for 12.5 +/- 4.0 months
Number of subjects: 40
Study 10097932 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14.4 +/- 3.8 months
Number of subjects: 40
Study 10097932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA)
Number of subjects: 40
Study 10097932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8732610 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain bupivacaine (group 1)
Number of subjects: 22
Study 8732610 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with adrenaline (group 2)
Number of subjects: 22
Study 1768544 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 40 mg kg‐1
Number of subjects: 38
Study 1768544 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Number of subjects: 38
Study 1768544 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulphate 40 mg kg‐1 and Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Number of subjects: 38
Study 6763455 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 16
Study 6763455 — intervention group
Group type: COMPARATOR
Intervention: Isopaque Coronar
Number of subjects: 16
Study 31977278 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 120
Study 31738342 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Water, Sanitation and Hygiene (WASH)
Number of subjects: 224
Study 31738342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine (RVV)
Number of subjects: 224
Study 31738342 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteropathogen infections
Number of subjects: 224
Study 28317676 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5% ophthalmic solution for 1 week postoperative
Number of subjects: 104
Study 28317676 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1.5% ophthalmic solution for 1 month postoperative
Number of subjects: 104
Study 28317676 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 1-week and 1-month postoperative groups
Number of subjects: 104
Study 25820605 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet website access (Intervention Group)
Number of subjects: 74
Study 25820605 — intervention group
Group type: COMPARATOR
Intervention: Printed versions (Control Group)
Number of subjects: 74
Study 25820605 — intervention group
Group type: EXPERIMENTAL
Intervention: High interactions (HI)
Number of subjects: 74
Study 25820605 — intervention group
Group type: EXPERIMENTAL
Intervention: No interactions (NI)
Number of subjects: 74
Study 25820605 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 74
Study 24634627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral BoNT‐A injections (25 U per muscle) into the masseter muscles only (group A)
Number of subjects: 20
Study 24634627 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral BoNT‐A injections into both the masseter and temporalis muscles (group B)
Number of subjects: 20
Study 22865871 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral prednisolone (0.5 mg/kg) for 3 days
Number of subjects: 225
Study 22865871 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral prednisolone (2 mg/kg) for 3 days
Number of subjects: 225
Study 22865871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 19121875 — intervention group
Group type: EXPERIMENTAL
Intervention: Online instructional videos for teaching clinical nursing skills
Number of subjects: 0
Study 17442556 — intervention group
Group type: EXPERIMENTAL
Intervention: BacoMind (300 mg for first 15 days, 450 mg for next 15 days)
Number of subjects: 23
Study 15280341 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision board (decision aid)
Number of subjects: 201
Study 15280341 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 201
Study 11925573 — intervention group
Group type: EXPERIMENTAL
Intervention: PLUS Nursing Intervention
Number of subjects: 25
Study 11925573 — intervention group
Group type: COMPARATOR
Intervention: Standard Home Care
Number of subjects: 25
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V + 2.5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V + 5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V + 2.5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E2V + 5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V increased to 2 mg after 6 months + 2.5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2V increased to 2 mg after 6 months + 5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg MPA
Number of subjects: 419
Study 11193245 — intervention group
Group type: COMPARATOR
Intervention: 5 mg MPA
Number of subjects: 419
Study 8704381 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing education program including classroom presentations and follow-up activities
Number of subjects: 0
Study 1592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.1 mg/kg
Number of subjects: 11
Study 1592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 11
Study 1592778 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 11
Study 1592778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6703506 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium intravenously
Number of subjects: 33
Study 6703506 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (placebo)
Number of subjects: 33
Study 31315728 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous neuromuscular electrical stimulation (twice a day, 30 minutes each time)
Number of subjects: 60
Study 31315728 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 60
Study 29863741 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-designed simulation project (SDSP) and Good Catch and Error Reporting (GCER) program
Number of subjects: 49
Study 29863741 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 49
Study 26110230 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Number of subjects: 28
Study 26110230 — intervention group
Group type: COMPARATOR
Intervention: Strength Training
Number of subjects: 28
Study 24389523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (AER)
Number of subjects: 262
Study 24389523 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic + Resistance training (AER + RES)
Number of subjects: 262
Study 24389523 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RES)
Number of subjects: 262
Study 22762857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacy dispensing data utilized)
Number of subjects: 487
Study 22762857 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard admission process without community pharmacy data)
Number of subjects: 487
Study 22762857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 487
Study 20631558 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2949
Study 20631558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2949
Study 18703813 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent hyperglycemia
Number of subjects: 748
Study 18703813 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed hyperglycemia at 24 hours
Number of subjects: 748
Study 18703813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia at baseline only
Number of subjects: 748
Study 18703813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic patterns of hyperglycemia in patients with diabetes
Number of subjects: 748
Study 15936036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol 20%, 100 ml every 4 h for 5 days, tapered in the next 2 days
Number of subjects: 128
Study 15936036 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 128